AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

⚠ Buying the Pipeline at Full PriceHigh threat

Gilead Sciences (GILD) — threat to the moat

Gilead has paid full price for Kite, Immunomedics and Forty Seven, wrote off about $8.65 billion of Immunomedics alone, and spent $11.3 billion more in the first half of 2026.

Gilead's main risk after Medicare is its own acquisition habit. Over the past decade it has paid full prices for pipelines that have so far returned far less than they cost, and in 2026 it paid again.

Gilead acquisition prices and what they wrote off or sold ($bn)20.6Immunomedics price8.65Its IPR&Dimpaired1.4Trodelvy 2025 sales11.2Kite price1.8Cell therapy2025 salesGilead Forms 10-K FY2018, FY2020, FY2022, FY2024, FY2025; Form 10-Q Q2 2026
Two large purchases, and annual sales a fraction of either price.

The record is in the filings. Kite cost $11,155 million in 20171; its cell therapies sold $1,839 million in 2025, down from $1,973 million2. Immunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D3; impairments of $2.7 billion in 20224, $2.4 billion and $1.8 billion in 20245 and $1.75 billion in 20266 total about $8.65 billion7, while Trodelvy sold $1,397 million in 20258. Forty Seven cost about $4.7 billion in 2020, with a $4.5 billion IPR&D charge9. CymaBay brought $3.8 billion of acquired IPR&D in 202410, and MYR a $590 million impairment in 202511.

In the first half of 2026 Gilead expensed $11,290 million of acquired IPR&D12: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro13. That turned a profitable business into a guided 2026 GAAP loss of $3.40 to $3.75 a share14.

The logic of the spending is sound: Biktarvy's exclusivity ends in 2036, and a company with one franchise must find another. The execution is the problem, and the cumulative bill is set out under What the Market Isn't Pricing In.

The 2026 deals were structured to share some of the risk. Ouro Medicines cost $1.675 billion upfront, "equally shared" with Lakefront, which will also share the milestones15, and Tubulis carries up to about $1.9 billion of contingent payments16. Those terms tie part of the price to success. The Arcellx price, by contrast, was mostly paid in cash at closing17.

The test of the 2026 round is simple. If anito-cel and the Tubulis conjugates together are not selling $1.5 billion a year by 2030, Gilead will have spent another decade's free cash on a second franchise that does not arrive.

The number that tests this threat
Reported
Acquired IPR&D, latest quarter
$11,183M (Q2 2026), from $61M a year earlier

The pace of buying; a repeat of this scale before the 2026 deals produce revenue would mean the habit, not the strategy, is driving.

Source: Gilead Sciences Q2 2026 results release ↗
References
  1. ReportedKite cost $11,155 million in 2017; its cell therapies sold $1,839 million in 2025, down from $1,973 million.
    Gilead Sciences Form 10-K for 2018 - the Kite Pharma acquisition at $180 a share ($11,155 million) and product sales of Harvoni and Epclusa for 2016-2018. — FY2018 · publ. February 2019 · source ↗
  2. ReportedKite cost $11,155 million in 2017; its cell therapies sold $1,839 million in 2025, down from $1,973 million.
    Gilead Sciences Form 10-K for 2025 - revenue by product, product group and region (Note 2) and the MD&A discussion of product sales. — FY2025 · publ. 24 February 2026 · source ↗
  3. ReportedImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Gilead Sciences Form 10-K for 2020 - the Immunomedics ($20.6 billion) and Forty Seven (about $4.7 billion) acquisitions, acquired IPR&D and the 94.7% effective tax rate. — FY2020 · publ. February 2021 · source ↗
  4. ReportedImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Gilead Sciences Form 10-K for 2022 - the $2.7 billion partial impairment of Trodelvy IPR&D. — FY2022 · publ. February 2023 · source ↗
  5. ReportedImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Gilead Sciences Form 10-K for 2024 - the Trodelvy IPR&D impairments of $2.4 billion and $1.8 billion, the CymaBay acquisition and the 2024 income statement. — FY2024 · publ. February 2025 · source ↗
  6. ReportedImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  7. Moat Explorer calcImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Moat Explorer calculation from Gilead Sciences reported figures ($ millions unless stated). HIV and Biktarvy: HIV share of total revenues 20,752 / 29,443 = 70.5% (2025); of product sales 20,752 / 28,915 = 71.8%; 16,438 / 22,449 = 73.2% (2019); 16,315 / 27,305 = 59.8% (2021); 18,175 / 27,116 = 67.0% (2023); 19,612 / 28,754 = 68.2% (2024). Biktarvy share of total revenues 14,334 / 29,443 = 48.7%; of HIV 14,334 / 20,752 = 69.1%; Biktarvy US 11,467 / 14,334 = 80.0%; Biktarvy growth 2025 14,334 / 13,423 - 1 = +6.8%; 2019-2025 14,334 / 4,738 = 3.0 times, (3.03)^(1/6) - 1 = about 20% a year. Other HIV 20,752 - 14,334 = 6,418; HIV other than Biktarvy, Descovy, Genvoya and Odefsey 20,752 - 14,334 - 2,758 - 1,498 - 1,167 = 995; Veklury plus Other plus royalties 911 + 799 + 527 = 2,237. Genvoya 1,498 / 3,931 - 1 = -61.9%. HIV growth 2019-2025 20,752 / 16,438 - 1 = +26.2%, about 4.0% a year; 2021 16,315 / 16,938 - 1 = -3.7%; 2023 18,175 / 17,194 - 1 = +5.7%; 2024 19,612 / 18,175 - 1 = +7.9%; 2025 20,752 / 19,612 - 1 = +5.8%, about 6%; H1 2026 10,723 / 9,675 - 1 = +10.8%; Q2 2026 5,693 / 5,088 - 1 = +11.9%. Descovy 2025 2,758 / 2,113 - 1 = +30.5%, about 31%; Q2 2026 967 / 653 - 1 = +48.1%; Descovy over Yeztugo Q2 2026 967 / 232 = 4.2, about four times. Yeztugo Q1 2026 = H1 397 - Q2 232 = 165; Yeztugo over Biktarvy H1 2026 397 / 7,133 = 5.6%, about 6%. US HIV 16,904 / 20,752 = 81.5%, about 81%; US product sales 20,816 / 28,915 = 72.0%; Europe 4,617 / 28,915 = 16.0%. Gilead HIV growth Q2 2026 +11.9% less ViiV +11% = about +1 point. Exclusivity: Descovy + Vemlidy + Odefsey 2,758 + 1,070 + 1,167 = 4,995, about $5.0bn, / 29,443 = 17.0% of revenue; Descovy + Vemlidy 2,758 + 1,070 = 3,828; Vemlidy share of Liver Disease 1,070 / 3,217 = 33.3%, a third; 2025 sales by primary US patent window: Tecartus 344 + Genvoya 1,498 = 1,842 (2027-2029); Trodelvy 1,397 + Descovy 2,758 + Vemlidy 1,070 + Odefsey 1,167 + sofosbuvir/velpatasvir 1,272 = 7,664 (2028-2033); Biktarvy 14,334 (2036). Hepatitis C 2015 Harvoni 13,864 + Sovaldi 5,276 = 19,140, / product sales 32,151 = 59.5%, about 60%; product sales 2018 21,677 / 32,151 - 1 = -32.6%; Liver Disease 2025 3,217 / 19,140 = 16.8%, about 17%, a sixth. Liver Disease 2019 HCV 2,936 + HBV/HDV 742 = 3,678; 2020 2,064 + 860 = 2,924. Price: gross product sales 2025 28,915 + 19,953 = 48,868, about $48.9bn; 2024 28,610 + 17,776 = 46,386; net product sales growth 28,915 / 28,610 - 1 = +1.1%, about 1%; gross-to-net deductions 19,953 / 17,776 - 1 = +12.2%; accrued rebates 4,337 / 3,892 - 1 = +11.4%, about 11%; rebates and chargebacks over net product sales 17.5bn / 28,915 = 60.5%, about 60% (2025); 15.5bn / 28,610 = 54.2% (2024). H1 2026 capital expenditure = operating cash flow 6,117 - free cash flow 5,859 = 258. Three wholesalers 29% + 24% + 21% = 74% of gross product sales (2025); 29% + 23% + 21% = 73% (2024). Hepatitis C share of revenue 1,272 / 29,443 = 4.3%, about 4%; sofosbuvir/velpatasvir 2025 1,272 / 1,596 - 1 = -20.3%, a fifth; Mavyret 1,317 / 1,311 - 1 = +0.5%. Cash and capital: free cash flow over revenue 9,456 / 29,443 = 32.1%, about 32%; dividends paid over free cash flow 4,003 / 9,456 = 42.3%, about 42%; free cash flow left after dividends and buybacks 9,456 - 4,003 - 1,922 = 3,531. Dividend per share (3.16 / 1.29)^(1/10) - 1 = 9.4% a year; increases 1.84 / 1.29 - 1 = +42.6% (2016); 2.72 / 2.52 - 1 = +7.9% (2020); 3.00 / 2.92 - 1 = +2.7% (2023); 3.08 / 3.00 - 1 = +2.7% (2024); 3.16 / 3.08 - 1 = +2.6% (2025); quarterly 0.82 / 0.79 - 1 = +3.8% (2026). Buybacks 2015-2016 10,002 + 11,001 = 21,003, about $21bn; year-end market value 2016 over 2015 94.34 / 145.83 - 1 = -35.3%, about a third. Net debt 31 December 2025 = total debt 24,937 - cash and marketable debt securities 10,605 = 14,332; 30 June 2026 = 26,246 - 3,179 = 23,067; net debt over 2025 free cash flow 23,067 / 9,456 = 2.4 years. Interest over operating income 1,024 / 10,022 = 10.2%, about a tenth (2025); 977 / 1,662 = 58.8%, more than half (2024). Gilead stockholders equity 11,829 / 22,703 - 1 = -47.9%, about 48%; return on equity 2025 8,510 / ((19,330 + 22,703) / 2 = 21,017) = 40.5%. Acquisitions: Trodelvy IPR&D impairments 2.7bn (2022) + 2.4bn + 1.8bn (2024) + 1.75bn (2026) = 8.65bn of 15.8bn recorded = 54.7%; Trodelvy Q1 2026 = H1 859 - Q2 457 = 402; Kite plus Immunomedics 11,155 + 20,600 = 31,755, over $31bn; cell therapy 2025 1,839 / 1,973 - 1 = -6.8%; Arcellx IPR&D 7.0bn / cell therapy 2025 1.839bn = 3.8 years. Acquired IPR&D 2019 5,051 + 2020 5,856 + 2021 939 + 2022 944 + 2023 1,155 + 2024 4,663 + 2025 1,024 + H1 2026 11,290 = 30,922, about $30.9bn; acquired IPR&D 2019-2025 alone = 30,922 - 11,290 = 19,632; Biktarvy 2025 US 11,467 + outside US 1,676 + 1,190 = 14,334, all other revenues 29,443 - 14,334 = 15,109 (shown 15.1); net income 2019-2025 5,386 + 123 + 6,225 + 4,592 + 5,665 + 480 + 8,510 = 30,981, about $31.0bn. Revenue lines: Liver Disease share 3,217 / 29,443 = 10.9%, about 11%; Oncology share 3,236 / 29,443 = 11.0%; Oncology 2020 cell therapy 607 + Trodelvy 49 = 656; Oncology 2025 3,236 / 3,289 - 1 = -1.6%, about 2%; 2019-2025 3,236 / 456 = 7.1 times, about sevenfold. Veklury 2021 5,565 / 27,305 = 20.4%, about a fifth; 2025 911 / 29,443 = 3.1%; product sales 2021-2025 28,915 / 27,008 - 1 = +7.1%; excluding Veklury (28,915 - 911 = 28,004) / (27,008 - 5,565 = 21,443) - 1 = +30.6%, about 31%. Other product sales plus royalty, contract and other revenues: 1,547 + 330 = 1,877 (2019); 1,026 + 334 = 1,360; 1,027 + 297 = 1,324; 946 + 299 = 1,245; 859 + 182 = 1,041; 889 + 144 = 1,033; 799 + 527 = 1,326 (2025). Bands sum to total revenues: 2025 20,752 + 3,217 + 3,236 + 911 + 1,326 = 29,442 against reported 29,443 (rounding); 2019 16,438 + 3,678 + 456 + 0 + 1,877 = 22,449. Non-HIV revenue 29,443 - 20,752 = 8,691, / 29,443 = 29.5%. Valuation and earnings: trailing twelve months to June 2026 revenue 29,443 - H1 2025 13,749 + H1 2026 14,763 = 30,457; net income 8,510 - 3,275 + (-8,475) = -3,240; diluted EPS 6.78 - 2.61 + (-6.82) = -2.65. Year-end market value over net income and revenue: 2015 145.83bn / 18,108 = 8.05, / 32,639 = 4.47; 2016 94.34 / 13,501 = 6.99, / 30,390 = 3.10; 2017 93.58 / 4,628 = 20.2, / 26,107 = 3.58; 2018 80.92 / 5,455 = 14.8, / 22,127 = 3.66; 2019 82.21 / 5,386 = 15.3, / 22,449 = 3.66; 2020 73.03 / 123 = 594, / 24,689 = 2.96; 2021 91.08 / 6,225 = 14.6, / 27,305 = 3.34; 2022 107.68 / 4,592 = 23.4, / 27,281 = 3.95; 2023 100.94 / 5,665 = 17.8, / 27,116 = 3.72; 2024 115.12 / 480 = 240, / 28,754 = 4.00; 2025 152.28 / 8,510 = 17.9, / 29,443 = 5.17; October 2026 179.47bn / 30,457 = 5.89. 2026 product sales guidance midpoints (29,600 + 30,000) / 2 = 29,800 (February); (30,000 + 30,400) / 2 = 30,200 (May); (30,100 + 30,400) / 2 = 30,250 (August). Non-GAAP EPS guidance midpoint (-0.65 + -0.30) / 2 = -0.475, plus 9.08 of acquired IPR&D and tax per share = 8.61. Additional: dividends paid 3,918 / 3,809 - 1 = +2.9% (2024), 4,003 / 3,918 - 1 = +2.2% (2025); gross product sales 48,868 / 46,386 - 1 = +5.4%, about 5%; Epclusa 1,966 / 3,510 - 1 = -44.0%; US HIV over US product sales 16,904 / 20,816 = 81.2%; European HIV over European product sales 2,392 / 4,617 = 51.8%; analyst target 158.65 / 144.74 - 1 = +9.6%, about 10%; market value 2025 over 2024 152.28 / 115.12 - 1 = +32.3%, a third. AmBisome 509 / 533 - 1 = -4.5%. Biktarvy over HIV: 4,738 / 16,438 = 28.8% (2019); 8,624 / 16,315 = 52.9% (2021); 11,850 / 18,175 = 65.2% (2023). Descovy + Vemlidy + Odefsey: 1,500 + 488 + 1,655 = 3,643 (2019); 1,700 + 814 + 1,568 = 4,082 (2021); 1,985 + 862 + 1,350 = 4,197 (2023); 2,113 + 959 + 1,288 = 4,360 (2024). Apretude Q1 2026 = H1 260 - Q2 140 = 120 (GBP M). Livdelzi Q1 2026 = H1 300 - Q2 167 = 133 - cash, capital returns, debt, acquisitions and valuation. — FY2015-Q2 2026 · publ. October 2026 · source ↗
    Method: Arithmetic on figures reported in Gilead Sciences Forms 10-K, 10-Q and results releases, SEC XBRL, stockanalysis.com market values, and the GSK and AbbVie filings cited; each operand is stated in the source line.
  8. ReportedImmunomedics cost $20.6 billion in cash in 2020, with $15.8 billion assigned to IPR&D; impairments of $2.7 billion in 2022, $2.4 billion and $1.8 billion in 2024 and $1.75 billion in 2026 total about $8.65 billion, while Trodelvy sold $1,397 million in 2025.
    Gilead Sciences Form 10-K for 2025 - financial statements, MD&A and notes: income, margins, impairments, acquired IPR&D, cash flow, capital returns and debt. — FY2025 · publ. 24 February 2026 · source ↗
  9. ReportedForty Seven cost about $4.7 billion in 2020, with a $4.5 billion IPR&D charge.
    Gilead Sciences Form 10-K for 2020 - the Immunomedics ($20.6 billion) and Forty Seven (about $4.7 billion) acquisitions, acquired IPR&D and the 94.7% effective tax rate. — FY2020 · publ. February 2021 · source ↗
  10. ReportedCymaBay brought $3.8 billion of acquired IPR&D in 2024, and MYR a $590 million impairment in 2025.
    Gilead Sciences Form 10-K for 2024 - the Trodelvy IPR&D impairments of $2.4 billion and $1.8 billion, the CymaBay acquisition and the 2024 income statement. — FY2024 · publ. February 2025 · source ↗
  11. ReportedCymaBay brought $3.8 billion of acquired IPR&D in 2024, and MYR a $590 million impairment in 2025.
    Gilead Sciences Form 10-K for 2025 - financial statements, MD&A and notes: income, margins, impairments, acquired IPR&D, cash flow, capital returns and debt. — FY2025 · publ. 24 February 2026 · source ↗
  12. ReportedIn the first half of 2026 Gilead expensed $11,290 million of acquired IPR&D: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  13. ReportedIn the first half of 2026 Gilead expensed $11,290 million of acquired IPR&D: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  14. ReportedThat turned a profitable business into a guided 2026 GAAP loss of $3.40 to $3.75 a share.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - income statement, EPS, cash flow, balance sheet and 2026 guidance. — Q2 2026 · publ. 4 August 2026 · source ↗
  15. ReportedOuro Medicines cost $1.675 billion upfront, "equally shared" with Lakefront, which will also share the milestones, and Tubulis carries up to about $1.9 billion of contingent payments.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  16. ReportedOuro Medicines cost $1.675 billion upfront, "equally shared" with Lakefront, which will also share the milestones, and Tubulis carries up to about $1.9 billion of contingent payments.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  17. ReportedThe Arcellx price, by contrast, was mostly paid in cash at closing.
    Gilead Sciences release of 28 April 2026, Form 8-K exhibit 99.1 - completion of the Arcellx acquisition for about $6.4 billion of cash net of cash acquired. — April 2026 · publ. 28 April 2026 · source ↗
Sources
Generated October 4, 2026